What We're Reading: Page 330
Industry reads hand-picked by our editors
Jul 11, 2016
-
LA Times
Inside an L.A. OxyContin ring that pushed more than 1 million pills. What the drugmaker knew
-
New York Times
A medical mystery of the best kind: major diseases are in decline
-
Reuters
False hope? China's military hospitals offer illegal experimental cures
-
The Sydney Morning Herald
AIDS epidemic 'over' in Australia, say peak bodies
Jul 08, 2016
-
Reuters
Japan's Eisai weighs legal action in UK cancer drug row
-
MIT Technology Review
Biomedicine Blood Tests That Spot Cancer DNA Offer “Quantitative Peace of Mind” for Survivors
-
Regulatory Focus
FDA to Restrict Compounders from Making Copies of Commercially Available Drugs
-
AP
Painkiller panel drops experts linked to pharmaceutical industry
Jul 07, 2016
Jul 06, 2016
-
Wall Street Journal
Valeant's new CEO brings familiar prescription
-
Stat
In clinical trials, for-profit review boards are taking over for hospitals. Should they?
-
Reuters
EU rivals vie to wrest drug and banking agencies from London
-
New York Times
California drug price plan is criticized by patient advocates
Jul 05, 2016
Jul 01, 2016
-
Endpoints
Where the money is: Biotech’s megahubs command VC’s billions
-
Wall Street Journal
Brexit Could Boost Drug Costs for Britain’s National Health Service
-
Reuters
UK drugs regulator halts approvals for Indian clinical trials firm
-
FiercePharma
Arena chops 100-plus jobs as it shifts its priorities from struggling Belviq
Jun 30, 2016
-
Forbes
Top Officials Aim To Reshape The FDA To Prepare For 'Avalanche' Of Cancer Products
-
Stat
New ovarian cancer drugs raise hope — but not for all
-
Bloomberg
This Gene-Editing Technology Will Change the World. But Who Gets the Credit?
-
Boston Business Journal
Cambridge diagnostic firm to double size of 'Moonshot' cancer database
Previous
